Article
Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia
16 Sept 2021
Abstract excerpt
Despite considerable growth in our understanding of the heterogeneous biology and pathogenesis of acute myeloid leukemia (AML) in recent decades, for nearly forty years, little progress was gained in the realm of novel therapeutics. Since 2017, however, nine agents have been FDA-approved for patients with AML in both the upfront and relapsed/refractory (R/R) settings. Most of these compounds function as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
